Stacey R. Gerben
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stacey R. Gerben has a total of 317 co-authors. Here are the top co-authors by number of shared publications:
- David Baker
Department of Biochemistry, University of Washington, Seattle, WA, USA
17 shared publications - Asim K. Bera
Department of Biochemistry, University of Washington, Seattle, WA, USA
12 shared publications - Alex Kang
Department of Biochemistry, University of Washington, Seattle, WA, USA
11 shared publications - Analisa Murray
Department of Biochemistry, University of Washington, Seattle, USA
7 shared publications - Xinting Li
Department of Biochemistry, University of Washington, Seattle, WA, USA
6 shared publications - David Juergens
Department of Biochemistry, University of Washington, Seattle, USA
5 shared publications
Latest Publications
- 14 October 2026
- Published by Springer Nature in Nature
- p. 1-10
Computational design of metalloproteases
- 14 October 2026
- Published by Springer Nature in Nature
- p. 1-10
Computational design of metalloproteases
- 2 June 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (23) , 23530-23539
De Novo Design of Near-Infrared Fluorescence-Activating Proteins
Protein-based fluorescence imaging is a powerful modality for visualizing diverse biological processes. Biological imaging in the near-infrared (NIR, 800–1000 nm) and shortwave infrared (SWIR, 1000–2000 nm) ranges confers a number of photophysical advantages, but remains a challenge in practice due to the dearth of suitable protein probes in these optical windows. To address this limitation, we sought to develop a general approach integrating computational protein design with organic synthesis for creating long-wavelength fluorescence-activating proteins from scratch. We used this approach to de novo design proteins that specifically bind to synthetic merocyanine dyes, forming Schiff base covalent linkages, which when protonated activate fluorescence with large redshifts in both excitation and emission wavelengths. We describe a designed far-red fluorescence-activating protein, MC7BP34, with a brightness greater than that of existing fluorescent proteins in a similar wavelength range, and an NIR design MC9BP81 with excitation at 892 nm and emission extending into the SWIR range with higher contrast and imaging sensitivity in vivo than the previously developed iRFP720 (excitation 672 nm) owing to the reduced tissue autofluorescence at longer wavelengths. Our results are a substantial step toward genetically encodable probes in the SWIR region, and our approach lays the groundwork for the development of NIR biosensors for specific biological applications.
- 2 June 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (23) , 23530-23539
De Novo Design of Near-Infrared Fluorescence-Activating Proteins
Protein-based fluorescence imaging is a powerful modality for visualizing diverse biological processes. Biological imaging in the near-infrared (NIR, 800–1000 nm) and shortwave infrared (SWIR, 1000–2000 nm) ranges confers a number of photophysical advantages, but remains a challenge in practice due to the dearth of suitable protein probes in these optical windows. To address this limitation, we sought to develop a general approach integrating computational protein design with organic synthesis for creating long-wavelength fluorescence-activating proteins from scratch. We used this approach to de novo design proteins that specifically bind to synthetic merocyanine dyes, forming Schiff base covalent linkages, which when protonated activate fluorescence with large redshifts in both excitation and emission wavelengths. We describe a designed far-red fluorescence-activating protein, MC7BP34, with a brightness greater than that of existing fluorescent proteins in a similar wavelength range, and an NIR design MC9BP81 with excitation at 892 nm and emission extending into the SWIR range with higher contrast and imaging sensitivity in vivo than the previously developed iRFP720 (excitation 672 nm) owing to the reduced tissue autofluorescence at longer wavelengths. Our results are a substantial step toward genetically encodable probes in the SWIR region, and our approach lays the groundwork for the development of NIR biosensors for specific biological applications.
- Open Access
Computational design of metalloproteases
De novo design of enzymes that cleave amide bonds represents a major challenge 1–2 . Here we use RFdiffusion methods 3–4 to de novo design proteins with water activating zinc based active sites adjacent to a peptide substrate binding pocket. Of 135 designs tested, 36% catalyze cleavage of their cognate peptide substrates at the targeted scissile bond. The best design accelerates peptide-bond hydrolysis by more than 10 8 -fold relative to the uncatalyzed reaction; four substitutions increase this acceleration to over 10 10 -fold by improving active-site preorganization 5 . We use this approach to design metalloproteases that selectively cleave the human disease associated proteins TDP-43, amyloid-β, and serum amyloid A, with rate enhancements of up to 10 9 -fold. We further design caged cytokines and receptor antagonists that are selectively activated by the designed proteases, enabling bioorthogonal control of cell state. Thus, de novo design can yield highly active, programmable proteases with applications in therapeutics, biotechnology, and bioremediation.
Open AccessComputational design of metalloproteases
De novo design of enzymes that cleave amide bonds represents a major challenge 1–2 . Here we use RFdiffusion methods 3–4 to de novo design proteins with water activating zinc based active sites adjacent to a peptide substrate binding pocket. Of 135 designs tested, 36% catalyze cleavage of their cognate peptide substrates at the targeted scissile bond. The best design accelerates peptide-bond hydrolysis by more than 10 8 -fold relative to the uncatalyzed reaction; four substitutions increase this acceleration to over 10 10 -fold by improving active-site preorganization 5 . We use this approach to design metalloproteases that selectively cleave the human disease associated proteins TDP-43, amyloid-β, and serum amyloid A, with rate enhancements of up to 10 9 -fold. We further design caged cytokines and receptor antagonists that are selectively activated by the designed proteases, enabling bioorthogonal control of cell state. Thus, de novo design can yield highly active, programmable proteases with applications in therapeutics, biotechnology, and bioremediation.
- 26 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (111) , eadx1582
Design of a potent interleukin-21 mimic for cancer immunotherapy
Long-standing goals of cancer immunotherapy are to activate cytotoxic antitumor T cells across a range of affinities for tumor antigens while suppressing regulatory T cells. Computational protein design has enabled the precise tailoring of proteins to meet specific needs. Here, we report a de novo designed IL-21 mimic, 21h10, with high stability and signaling potency in humans and mice. In murine and ex vivo human organotypic tumor models, 21h10 showed robust antitumor activity, with more prolonged signaling and stronger antitumor activity than native IL-21. 21h10 induced pancreatitis that could be mitigated by TNF blockade without compromising antitumor efficacy. Although antidrug antibodies to 21h10 formed, they were not neutralizing. 21h10 induced highly cytotoxic T cells with a range of affinities, robustly expanding intratumoral low-affinity cytotoxic T cells and driving high expression of IFN-γ and granzyme B compared with native IL-21, while increasing the frequency of IFN-γ + T helper 1 cells and reducing regulatory T cells. The full human-mouse cross-reactivity, high stability and potency, and low-affinity antitumor responses support the translational potential of 21h10.
- 26 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (111) , eadx1582
Design of a potent interleukin-21 mimic for cancer immunotherapy
Long-standing goals of cancer immunotherapy are to activate cytotoxic antitumor T cells across a range of affinities for tumor antigens while suppressing regulatory T cells. Computational protein design has enabled the precise tailoring of proteins to meet specific needs. Here, we report a de novo designed IL-21 mimic, 21h10, with high stability and signaling potency in humans and mice. In murine and ex vivo human organotypic tumor models, 21h10 showed robust antitumor activity, with more prolonged signaling and stronger antitumor activity than native IL-21. 21h10 induced pancreatitis that could be mitigated by TNF blockade without compromising antitumor efficacy. Although antidrug antibodies to 21h10 formed, they were not neutralizing. 21h10 induced highly cytotoxic T cells with a range of affinities, robustly expanding intratumoral low-affinity cytotoxic T cells and driving high expression of IFN-γ and granzyme B compared with native IL-21, while increasing the frequency of IFN-γ + T helper 1 cells and reducing regulatory T cells. The full human-mouse cross-reactivity, high stability and potency, and low-affinity antitumor responses support the translational potential of 21h10.
- Top Cited PapersOpen Access
- 17 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6757) , eadr8063
Design of intrinsically disordered region binding proteins
Intrinsically disordered proteins and peptides play key roles in biology, but a lack of defined structures and high variability in sequence and conformational preferences have made targeting such systems challenging. We describe a general approach for designing proteins that bind intrinsically disordered protein regions in diverse extended conformations with side chains fitting into complementary binding pockets. We used the approach to design binders for 39 highly diverse unstructured targets, including polar targets, and obtained designs with 100-picomolar to 100-nanomolar affinities in 34 cases, testing ~22 designs per target. The designs function in cells and as detection reagents and are specific for their intended targets in all-by-all binding experiments. Our approach is a major step toward a general solution to the intrinsically disordered protein and peptide recognition problem.
- 17 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6757) , eadr8063
Top Cited PapersOpen AccessDesign of intrinsically disordered region binding proteins
Intrinsically disordered proteins and peptides play key roles in biology, but a lack of defined structures and high variability in sequence and conformational preferences have made targeting such systems challenging. We describe a general approach for designing proteins that bind intrinsically disordered protein regions in diverse extended conformations with side chains fitting into complementary binding pockets. We used the approach to design binders for 39 highly diverse unstructured targets, including polar targets, and obtained designs with 100-picomolar to 100-nanomolar affinities in 34 cases, testing ~22 designs per target. The designs function in cells and as detection reagents and are specific for their intended targets in all-by-all binding experiments. Our approach is a major step toward a general solution to the intrinsically disordered protein and peptide recognition problem.
- Top Cited PapersOpen Access
- 20 June 2025
- Published by Springer Nature in Nature Chemical Biology
- Vol. 21 (12) , 1948-1956
Accurate de novo design of high-affinity protein-binding macrocycles using deep learning
Developing macrocyclic binders to therapeutic proteins typically relies on large-scale screening methods that are resource intensive and provide little control over binding mode. Despite progress in protein design, there are currently no robust approaches for de novo design of protein-binding macrocycles. Here we introduce RFpeptides, a denoising diffusion-based pipeline for designing macrocyclic binders against protein targets of interest. We tested 20 or fewer designed macrocycles against each of four diverse proteins and obtained binders with medium to high affinity against all targets. For one of the targets, Rhombotarget A (RbtA), we designed a high-affinity binder ( K d < 10 nM) despite starting from the predicted target structure. X-ray structures for macrocycle-bound myeloid cell leukemia 1, γ-aminobutyric acid type A receptor-associated protein and RbtA complexes match closely with the computational models, with a Cα root-mean-square deviation < 1.5 Å to the design models. RFpeptides provides a framework for rapid and custom design of macrocyclic peptides for diagnostic and therapeutic applications.
- 20 June 2025
- Published by Springer Nature in Nature Chemical Biology
- Vol. 21 (12) , 1948-1956
Top Cited PapersOpen AccessAccurate de novo design of high-affinity protein-binding macrocycles using deep learning
Developing macrocyclic binders to therapeutic proteins typically relies on large-scale screening methods that are resource intensive and provide little control over binding mode. Despite progress in protein design, there are currently no robust approaches for de novo design of protein-binding macrocycles. Here we introduce RFpeptides, a denoising diffusion-based pipeline for designing macrocyclic binders against protein targets of interest. We tested 20 or fewer designed macrocycles against each of four diverse proteins and obtained binders with medium to high affinity against all targets. For one of the targets, Rhombotarget A (RbtA), we designed a high-affinity binder ( K d < 10 nM) despite starting from the predicted target structure. X-ray structures for macrocycle-bound myeloid cell leukemia 1, γ-aminobutyric acid type A receptor-associated protein and RbtA complexes match closely with the computational models, with a Cα root-mean-square deviation < 1.5 Å to the design models. RFpeptides provides a framework for rapid and custom design of macrocyclic peptides for diagnostic and therapeutic applications.
- Open Access
- 9 June 2025
- Published by Wiley in Advanced Materials
- Vol. 37 (34) , e2500872
De Novo Design of Integrin α5β1 Modulating Proteins to Enhance Biomaterial Properties
Integrin α5β1 is crucial for cell attachment and migration in development and tissue regeneration, and α5β1 binding proteins can have considerable utility in regenerative medicine and next‐generation therapeutics. We use computational protein design to create de novo α5β1‐specific modulating miniprotein binders, called NeoNectins, that bind to and stabilize the open state of α5β1. When immobilized onto titanium surfaces and throughout 3D hydrogels, the NeoNectins outperform native fibronectin (FN) and RGD peptides in enhancing cell attachment and spreading, and NeoNectin‐grafted titanium implants outperformed FN‐ and RGD‐grafted implants in animal models in promoting tissue integration and bone growth. NeoNectins should be broadly applicable for tissue engineering and biomedicine.
- 9 June 2025
- Published by Wiley in Advanced Materials
- Vol. 37 (34) , e2500872
Open AccessDe Novo Design of Integrin α5β1 Modulating Proteins to Enhance Biomaterial Properties
Integrin α5β1 is crucial for cell attachment and migration in development and tissue regeneration, and α5β1 binding proteins can have considerable utility in regenerative medicine and next‐generation therapeutics. We use computational protein design to create de novo α5β1‐specific modulating miniprotein binders, called NeoNectins, that bind to and stabilize the open state of α5β1. When immobilized onto titanium surfaces and throughout 3D hydrogels, the NeoNectins outperform native fibronectin (FN) and RGD peptides in enhancing cell attachment and spreading, and NeoNectin‐grafted titanium implants outperformed FN‐ and RGD‐grafted implants in animal models in promoting tissue integration and bone growth. NeoNectins should be broadly applicable for tissue engineering and biomedicine.
- Top Cited PapersOpen Access
- 21 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 4730
Cyclic peptide structure prediction and design using AlphaFold2
Small cyclic peptides have gained significant traction as a therapeutic modality; however, the development of deep learning methods for accurately designing such peptides has been slow, mostly due to the lack of sufficiently large training sets. Here, we introduce AfCycDesign, a deep learning approach for accurate structure prediction, sequence redesign, and de novo hallucination of cyclic peptides. Using AfCycDesign, we identified over 10,000 structurally-diverse designs predicted to fold into the designed structures with high confidence. X-ray crystal structures for eight tested de novo designed sequences match very closely with the design models (RMSD < 1.0 Å), highlighting the atomic level accuracy in our approach. Further, we used the set of hallucinated peptides as starting scaffolds to design binders with nanomolar IC50 against MDM2 and Keap1. The computational methods and scaffolds developed here provide the basis for the custom design of peptides for diverse protein targets and therapeutic applications.
- 21 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 4730
Top Cited PapersOpen AccessCyclic peptide structure prediction and design using AlphaFold2
Small cyclic peptides have gained significant traction as a therapeutic modality; however, the development of deep learning methods for accurately designing such peptides has been slow, mostly due to the lack of sufficiently large training sets. Here, we introduce AfCycDesign, a deep learning approach for accurate structure prediction, sequence redesign, and de novo hallucination of cyclic peptides. Using AfCycDesign, we identified over 10,000 structurally-diverse designs predicted to fold into the designed structures with high confidence. X-ray crystal structures for eight tested de novo designed sequences match very closely with the design models (RMSD < 1.0 Å), highlighting the atomic level accuracy in our approach. Further, we used the set of hallucinated peptides as starting scaffolds to design binders with nanomolar IC50 against MDM2 and Keap1. The computational methods and scaffolds developed here provide the basis for the custom design of peptides for diverse protein targets and therapeutic applications.
- Open Access
- 26 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-12
Design of high-affinity binders to immune modulating receptors for cancer immunotherapy
Immune receptors have emerged as critical therapeutic targets for cancer immunotherapy. Designed protein binders can have high affinity, modularity, and stability and hence could be attractive components of protein therapeutics directed against these receptors, but traditional Rosetta based protein binder methods using small globular scaffolds have difficulty achieving high affinity on convex targets. Here we describe the development of helical concave scaffolds tailored to the convex target sites typically involved in immune receptor interactions. We employed these scaffolds to design proteins that bind to TGFβRII, CTLA-4, and PD-L1, achieving low nanomolar to picomolar affinities and potent biological activity following experimental optimization. Co-crystal structures of the TGFβRII and CTLA-4 binders in complex with their respective receptors closely match the design models. These designs should have considerable utility for downstream therapeutic applications.
- 26 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-12
Open AccessDesign of high-affinity binders to immune modulating receptors for cancer immunotherapy
Immune receptors have emerged as critical therapeutic targets for cancer immunotherapy. Designed protein binders can have high affinity, modularity, and stability and hence could be attractive components of protein therapeutics directed against these receptors, but traditional Rosetta based protein binder methods using small globular scaffolds have difficulty achieving high affinity on convex targets. Here we describe the development of helical concave scaffolds tailored to the convex target sites typically involved in immune receptor interactions. We employed these scaffolds to design proteins that bind to TGFβRII, CTLA-4, and PD-L1, achieving low nanomolar to picomolar affinities and potent biological activity following experimental optimization. Co-crystal structures of the TGFβRII and CTLA-4 binders in complex with their respective receptors closely match the design models. These designs should have considerable utility for downstream therapeutic applications.
- Top Cited PapersOpen Access
- 15 January 2025
- Published by Springer Nature in Nature
- Vol. 639 (8053) , 225-231
De novo designed proteins neutralize lethal snake venom toxins
Snakebite envenoming remains a devastating and neglected tropical disease, claiming over 100,000 lives annually and causing severe complications and long-lasting disabilities for many more1,2. Three-finger toxins (3FTx) are highly toxic components of elapid snake venoms that can cause diverse pathologies, including severe tissue damage3 and inhibition of nicotinic acetylcholine receptors, resulting in life-threatening neurotoxicity4. At present, the only available treatments for snakebites consist of polyclonal antibodies derived from the plasma of immunized animals, which have high cost and limited efficacy against 3FTxs5,6,7. Here we used deep learning methods to de novo design proteins to bind short-chain and long-chain α-neurotoxins and cytotoxins from the 3FTx family. With limited experimental screening, we obtained protein designs with remarkable thermal stability, high binding affinity and near-atomic-level agreement with the computational models. The designed proteins effectively neutralized all three 3FTx subfamilies in vitro and protected mice from a lethal neurotoxin challenge. Such potent, stable and readily manufacturable toxin-neutralizing proteins could provide the basis for safer, cost-effective and widely accessible next-generation antivenom therapeutics. Beyond snakebite, our results highlight how computational design could help democratize therapeutic discovery, particularly in resource-limited settings, by substantially reducing costs and resource requirements for the development of therapies for neglected tropical diseases.
- 15 January 2025
- Published by Springer Nature in Nature
- Vol. 639 (8053) , 225-231
Top Cited PapersOpen AccessDe novo designed proteins neutralize lethal snake venom toxins
Snakebite envenoming remains a devastating and neglected tropical disease, claiming over 100,000 lives annually and causing severe complications and long-lasting disabilities for many more1,2. Three-finger toxins (3FTx) are highly toxic components of elapid snake venoms that can cause diverse pathologies, including severe tissue damage3 and inhibition of nicotinic acetylcholine receptors, resulting in life-threatening neurotoxicity4. At present, the only available treatments for snakebites consist of polyclonal antibodies derived from the plasma of immunized animals, which have high cost and limited efficacy against 3FTxs5,6,7. Here we used deep learning methods to de novo design proteins to bind short-chain and long-chain α-neurotoxins and cytotoxins from the 3FTx family. With limited experimental screening, we obtained protein designs with remarkable thermal stability, high binding affinity and near-atomic-level agreement with the computational models. The designed proteins effectively neutralized all three 3FTx subfamilies in vitro and protected mice from a lethal neurotoxin challenge. Such potent, stable and readily manufacturable toxin-neutralizing proteins could provide the basis for safer, cost-effective and widely accessible next-generation antivenom therapeutics. Beyond snakebite, our results highlight how computational design could help democratize therapeutic discovery, particularly in resource-limited settings, by substantially reducing costs and resource requirements for the development of therapies for neglected tropical diseases.